Related Experiment Videos
Ciclosporin A in acrodermatitis continua.
Dermatologica
|January 1, 1987
Summary
Ciclosporin A effectively treated severe pustular psoriasis (acrodermatitis continua type) in a patient resistant to multiple therapies. Complete remission was achieved rapidly, offering a new treatment option for this debilitating skin condition.
Area of Science:
- Dermatology
- Immunosuppressive Therapy
Background:
- Pustular psoriasis, specifically acrodermatitis continua, is a severe and chronic skin condition.
- Refractory cases often require multiple treatment modalities, with limited success in achieving complete remission.
Observation:
- A 58-year-old female presented with a 10-year history of severe pustular psoriasis (acrodermatitis continua type).
- The patient had undergone numerous treatments including methotrexate, systemic steroids, etretinate, colchicine, hydroxyurea, and PUVA, with no complete remissions.
Findings:
- Treatment with Ciclosporin A (initially 14 mg/kg/day, reduced to 7.5 mg/kg/day) resulted in complete remission within three weeks.
- This indicates Ciclosporin A's potent efficacy in managing severe, treatment-resistant pustular psoriasis.
Implications:
- Ciclosporin A presents a promising therapeutic option for severe acrodermatitis continua unresponsive to conventional treatments.
- Further monitoring is necessary to assess the long-term efficacy and safety of low-dose Ciclosporin A in maintaining remission.